行情

MRTX

MRTX

Mirati
NASDAQ

实时行情|Nasdaq Last Sale

136.76
-4.44
-3.14%
休市 16:00 11/26 EST
开盘
140.96
昨收
141.20
最高
144.32
最低
136.17
成交量
32.49万
成交额
--
52周最高
249.42
52周最低
131.47
市值
75.51亿
市盈率(TTM)
-14.3439
分时
5日
1月
3月
1年
5年
Mirati Therapeutics To Participate In Evercore ISI HealthCONx Conference Dec. 2 At 2:15 p.m. EST
Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, will take part in a fireside chat at the Evercore ISI HealthCONx Conference, which will be webcast on December 2 at 11:15 a.m. P.T. /
Benzinga · 4天前
Mirati Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will take part in a fireside chat at the Evercore ISI HealthCONx Conference, which will be webcast on December 2 at 11:15 a.m. P.T. / 2:15 p.m. E.T. David Meek, chief exe...
PR Newswire · 4天前
Mirati (MRTX), Verastem to Study Cancer Drugs for NSCLC
Zacks.com · 4天前
Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer
Mirati Therapeutics, Inc. (Nasdaq:MRTX), a clinical-stage targeted oncology company and Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced a non-exclusive clinical...
PR Newswire · 5天前
Expert Ratings For Mirati Therapeutics
Mirati Therapeutics (NASDAQ:MRTX) has observed the following analyst ratings within the last quarter:
Benzinga · 11/19 16:57
BMO Capital Initiates Coverage On Mirati Therapeutics with Outperform Rating, Announces Price Target of $187
BMO Capital analyst Evan Seigerman initiates coverage on Mirati Therapeutics (NASDAQ:MRTX) with a Outperform rating and announces Price Target of $187.
Benzinga · 11/19 10:39
Mirati (MRTX) to Begin Clinical Study in MTAP-Deleted Cancers
Mirati (MRTX) submits an investigational new drug application to the FDA for MRTX1719 for the treatment of methylthioadenosine phosphoylase-deleted cancers.
Zacks · 11/18 15:13
Mirati Therapeutics submits IND application for MRTX1719 to treat MTAP-deleted cancers
Mirati Therapeutics (NASDAQ:MRTX) has submitted an Investigational New Drug (IND) application to the FDA to evaluate its synthetic lethal PRMT5 inhibitor, MRTX1719, for the treatment of methylthioadenosine phosphoylase (MTAP)-deleted cancers.
Seekingalpha · 11/17 13:19
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解MRTX最新的财务预测,通过MRTX每股收益,每股净资产,每股现金流等数据分析Mirati近期的经营情况,然后做出明智的投资选择。
分析师评级

16位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

25.00%强力推荐
43.75%买入
25.00%中性
6.25%落后大盘
0.00%卖出
目标价格预测
分析师预测MRTX价格均价为220.08,最高价位300.00,最低价为171.00。
最高300.00
均价220.08
最低171.00
现价136.76
EPS
实际EPS
预期EPS
-2.58-1.94-1.29-0.65
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 308
机构持股: 6,394.56万
持股比例: 115.81%
总股本: 5,521.54万
类型机构数股数
增持
89
426.63万
建仓
41
79.10万
减持
79
303.87万
平仓
46
66.37万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+2.30%
制药与医学研究
+0.44%
高管信息
Chairman/Director
Faheem Hasnain
President
Charles Baum
Chief Executive Officer
David Meek
Chief Financial Officer
Vickie Reed
Executive Vice President/Chief Scientific Officer
James Christensen
Executive Vice President
Benjamin Hickey
Independent Director
Bruce Carter
Independent Director
Julie Cherrington
Independent Director
Aaron Davis
Independent Director
Henry Fuchs
Independent Director
Craig Johnson
Independent Director
Maya Martinez-Davis
Independent Director
Shalini Sharp
暂无数据
MRTX 简况
Mirati Therapeutics, Inc.是一家临床阶段的生物制药公司。该公司专注于开发靶向肿瘤的产品。该公司开发候选产品来应对癌症的遗传和免疫促进剂。其临床计划包括两个候选产品:MRTX849(一种Kirsten大鼠肉瘤(KRAS)G12C抑制剂)和Sitravatinib(一种多激酶抑制剂)。KRAS抑制剂计划专注于发现和开发针对KRAS G12C和G12D的小分子化合物。MRTX849设计用于抑制非小细胞肺癌(NSCLC)腺癌患者、结肠直肠癌(CRC)患者、胰腺癌患者以及其他一些难以治疗的癌症中存在的KRAS G12C突变。Sitravatinib是一种频谱选择性激酶抑制剂,旨在抑制受体酪氨酸激酶(RTK),包括TAM家族受体(TYRO3、Axl和Mer)、分裂家族受体(VEGFR2和KIT)和RET。

微牛提供Mirati Therapeutics Inc(NASDAQ-MRTX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的MRTX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易MRTX股票基本功能。